Miltenyi Biotec’s mission is to improve scientific understanding and medical progress. By developing innovative products that address the processes that are necessary for the study of immuno-oncology we help researchers advance science in these key areas as well as help clinicians to make the concept of cellular therapy a reality.
Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis, develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The Isolight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies. Isoplexis has partnered with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Modification System®, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.
HebeCell’s first-in-class proprietary 3D manufacture platform for human iPS-NK cells is feeder-free, designed for single-use-bioreactor at industrial scale. By eliminating exhaustive feeder-dependent expansion, our platform offers a truly viable unlimited source of immune cells with improved potency and simplified manufacture process. Our goal is to unlock the true power of NK cells in fighting cancer, autoimmune and infectious diseases.
The Jackson Laboratory
The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development.
Since our start in 2006, research and development efforts at Akron Biotech have led to discoveries that have fuelled the development of some of the most innovative products to support cell and gene therapy research, clinical development and commercialization. Now, Akron operates from a 14,000 sf facility in Boca Raton as a leader in innovation and cGMP manufacturing.
LUMICKS creates technologies for dynamic single-molecule and cell avidity analysis. Our latest instrument, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells, providing a new parameter for experimentally evaluating immune cell functionality and activation. With this technology, scientists can measure cell avidity and obtain predictive, reproducible, and high-throughput results to compare several types of immunotherapeutic strategies, including CAR T cells, TCR T cells, bispecific antibodies, and NK cells.
Want to evaluate killing kinetics with physiologically relevant effector cell to target cell ratios? Concerned about the possible confounding effects of labeling your cells? Introducing Maestro ZHT from Axion BioSystems, the world’s most advanced impedance-based real-time cell analysis platform. Over minutes or weeks gain unprecedented access to the kinetics of your biology. Straightforward and easy to use, any researcher can now track immune cell-mediated killing in 96- and 384-well plates.
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.
Be The Match
Your trusted partner empowering the discovery, development and delivery of next-generation therapies
Beacon Targeted Therapies
Beacon Targeted Therapies, a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world working in targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Find out more on how we can help you by visiting
Bio-Techne is a global life science company providing innovative products and resources for the research and clinical diagnostic communities. Our expertise across three operating divisions spans laboratory research, preclinical and clinical studies, and reagents for manufacturing therapeutic and diagnostic tests, making us uniquely suited to serve the immune cell therapy research community. We develop and manufacture NK cell isolation and expansion kits, specialized NK cell culture media, and high-quality proteins, and we have established ourselves as the world leader in immunoassays.
Avectas is a cell engineering business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique delivery technology platform, Solupore®, to enable the ex-vivo manufacture of gene modified cell therapy products, with partners. Solupore® is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality. The Solupore® technology is designed for use with mRNA, DNA, and proteins, including gene editing tools such as CRISPR. Solupore® achieves excellent engineering efficiencies for delivery of these payloads to primary T cells and NK cells for immuno-oncology and gene editing applications. Avectas is currently developing the clinical (cGMP) technology embodiment while enhancing its dataset, implementing its commercialization strategy and building out the team.